125
Participants
Start Date
December 8, 2017
Primary Completion Date
September 22, 2020
Study Completion Date
June 22, 2022
Pembrolizumab
IV infusion at the dose of 200 mg on day 1 every 3 weeks
cis/carboplatin and etoposide
Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
Ospedale S. Luigi Gonzaga - Universita Di Torino, Orbassano
Santa Croce e Carle General Hospital, Cuneo
Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille
Centre Regional Francois Baclesse, Caen
Istituto Europeo di Oncologia, Milan
Ospedale San Paolo, Milan
CHU de Brest, Brest
Azienda Ospedaliero-Universitaria Careggi, Florence
Centre Paul Strauss, Strasbourg
Centre Leon Berard, Lyon
Centre Hospitalier D'Annecy, Metz-Tessy
Centre Hospitalier d'Avignon - Hopital Duffaut, Avignon
Assistance Publique - Hopitaux de Paris - Hopital Avicenne, Paris
Centre Hopitalier Intercommunal De Creteil, Créteil
Gustave Roussy, Villejuif
Ospedale Cannizzaro, Catania
The Christie NHS Foundation Trust, Manchester
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital, Sheffield
Merck Sharp & Dohme LLC
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK